Eli Lilly and Company (LLY)
Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 66.2502
- Book/Share 26.5925
- PB 41.7334
- Debt/Equity 1.7865
- CurrentRatio 1.5463
- ROIC 0.286
- MktCap 992485244666.0
- FreeCF/Share 10.0576
- PFCF 110.0231
- PE 53.9306
- Debt/Assets 0.3698
- DivYield 0.0054
- ROE 1.0226
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | LLY | UBS | -- | Buy | -- | $1250 | Jan. 7, 2026 |
| Upgrade | LLY | Daiwa Securities | Neutral | Buy | -- | $1230 | Dec. 16, 2025 |
| Reiterated | LLY | BofA Securities | -- | Buy | $1286 | $1268 | Dec. 15, 2025 |
| Reiterated | LLY | Goldman | -- | Buy | $951 | $1145 | Dec. 15, 2025 |
| Initiation | LLY | Scotiabank | -- | Sector Outperform | -- | $1165 | Nov. 13, 2025 |
| Upgrade | LLY | Leerink Partners | Market Perform | Outperform | -- | $1104 | Nov. 10, 2025 |
| Reiterated | LLY | BMO Capital Markets | -- | Outperform | $840 | $930 | Oct. 20, 2025 |
| Upgrade | LLY | Erste Group | Hold | Buy | -- | -- | Oct. 14, 2025 |
| Downgrade | LLY | Berenberg | Buy | Hold | -- | $830 | Sept. 17, 2025 |
| Upgrade | LLY | HSBC Securities | Reduce | Hold | -- | $700 | Aug. 27, 2025 |
News
Eli Lilly and Novo Nordisk lower GLP-1 drug costs in new deal with Trump.
Published: November 06, 2025 by: Yahoo Finance
Sentiment: Positive
About Yahoo Finance: Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life. - Get the latest news and data at finance.yahoo.com - Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO) - Follow Yahoo Finance on social: X: http://twitter.com/YahooFinance Instagram: https://www.instagram.com/yahoofinance/?hl=en TikTok: https://www.tiktok.com/@yahoofinance?lang=en Facebook: https://www.facebook.com/yahoofinance/ LinkedIn: https://www.linkedin.com/company/yahoo-finance
Read More
Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk
Published: November 06, 2025 by: CNBC
Sentiment: Positive
President Donald Trump struck landmark deals with Eli Lilly and Novo Nordisk to slash the prices of their blockbuster weight loss drugs. Under the agreements, the monthly out-of-pocket cost of popular injections and upcoming pills could range from $50 to $350, depending on the dosage and insurance coverage a patient has.
Read More
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans
Published: November 06, 2025 by: PRNewsWire
Sentiment: Neutral
Medicare beneficiaries with obesity or overweight will have access to Zepbound and orforglipron, if approved, at $50 a month INDIANAPOLIS , Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an agreement with the U.S. government to expand access to its obesity medicines and reduce patient costs. The agreement builds on Lilly's longstanding commitment to finding solutions with policymakers that improve access to life-changing medicines.
Read More
Lilly, Novo Will Lower Obesity Drug Prices in Trump Deal
Published: November 06, 2025 by: Bloomberg Markets and Finance
Sentiment: Positive
Eli Lilly & Co. and Novo Nordisk A/S cut a deal with the Trump administration to lower prices on their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. President Donald Trump spoke about it in the Oval Office.
Read More
Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
Published: November 06, 2025 by: CNBC
Sentiment: Positive
President Donald Trump announced deals with Eli Lilly and Novo Nordisk to slash the prices of some of their obesity drugs, including upcoming pills, in a landmark effort to expand access to the costly blockbuster treatments. The agreements will lower prices of GLP-1 drugs on Medicare and Medicaid and offer the treatments directly to consumers at a discount on a website the Trump administration is launching in January 2026 called TrumpRx.gov.
Read More
Trump White House confirms pricing deal with weight-loss-drug giants Eli Lilly, Novo Nordisk
Published: November 06, 2025 by: Market Watch
Sentiment: Positive
President Donald Trump's administration confirmed Thursday that it has reached a deal with Eli Lilly and Novo Nordisk that aims to deliver lower prices for their popular GLP-1 drugs to certain Medicare and Medicaid beneficiaries and to users of TrumpRx.gov, the administration's new direct-to-consumer website.
Read More
Here's Why Eli Lilly (LLY) is a Strong Momentum Stock
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Lilly and Novo Nordisk near White House deal on obesity drug prices, Endpoints New reports
Published: November 04, 2025 by: Reuters
Sentiment: Positive
Eli Lilly and Novo Nordisk are preparing to announce new drug pricing deals with the White House, including for their blockbuster weight loss drugs, in return for coverage of products under Medicare, Endpoints New reported on Tuesday, citing sources familiar with the matter.
Read More
International Markets and Lilly (LLY): A Deep Dive for Investors
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Explore how Lilly's (LLY) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Read More
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Eli Lilly Has A Solid Upside Now After Its Q3 Earnings
Published: October 31, 2025 by: Seeking Alpha
Sentiment: Positive
Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin analogs. LLY posted a 54% YoY revenue jump and a 19% EPS beat, with management raising both sales and EPS guidance for the year. A strengthened drug pipeline, particularly for orforglipron's Phase III success, de-risks future earnings and promises sustained growth beyond 2027.
Read More
Eli Lilly's obesity and diabetes treatments fuel growth and spark bidding war
Published: October 31, 2025 by: Fast Company
Sentiment: Positive
The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.
Read More
Eli Lilly and Company (LLY) Q3 2025 Earnings Call Transcript
Published: October 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly and Company ( LLY ) Q3 2025 Earnings Call October 30, 2025 10:00 AM EDT Company Participants Mike Czapar - Director of Investor Relations David Ricks - Chairman, CEO & President Lucas Montarce - Executive VP & CFO Daniel Skovronsky - EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology Patrik Jonsson - Executive VP & President of Lilly International Ilya Yuffa - Executive VP and President of Lilly USA & Global Customer Capabilities Anne White - Executive VP & President of Lilly Neuroscience Kenneth Custer - Executive VP & President of Lilly Cardiometabolic …
Read More
Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year sales and earnings outlook.
Read More
Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Eli Lilly Boosts Its Outlook on High Demand for Popular Weight-Loss Drugs
Published: October 30, 2025 by: Investopedia
Sentiment: Positive
Strong sales of Eli Lilly's weight-loss treatments Mounjaro and Zepbound helped power strong quarterly earnings, and the drugmaker boosted its outlook.
Read More
Eli Lilly Q3 earnings and revenue top estimates, boosted by weight loss drug demand
Published: October 30, 2025 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY) on Thursday reported third quarter 2025 financial results that handily beat Wall Street forecasts, as the company continued to see strong demand for its weight loss drug Zepbound and diabetes treatment Mounjaro. The pharmaceutical giant's revenue for the quarter rose 54% year over year to $17.60 billion, surpassing the analyst consensus estimate of $16.01 billion, according to data provided by LSEG.
Read More
Eli Lilly Blows Away Q3 Earnings Expectations
Published: October 30, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Eli Lilly (NYSE: LLY) delivered a commanding third quarter, posting earnings and revenue that significantly exceeded expectations while raising full-year guidance.
Read More
Eli Lilly, Walmart to offer first retail pickup option for discounted vials of weight loss drug Zepbound
Published: October 29, 2025 by: CNBC
Sentiment: Positive
Eli Lilly and Walmart said they have teamed up to boost access to the pharma giant's weight loss drug Zepbound, allowing U.S. patients to access vials of the blockbuster injection at direct-to-consumer prices through retail locations for the first time. Starting in mid-November, cash-paying patients with a prescription can purchase single-dose vials of Zepbound at discounts of 50% or more through the retailer's nearly 4,600 pharmacy locations or via home delivery.
Read More
What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?
Published: October 29, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and fuel long-term growth.
Read More
Lilly and Walmart launch first retail pick-up option for weight-loss drug
Published: October 29, 2025 by: Reuters
Sentiment: Positive
Eli Lilly and Walmart said on Wednesday they are partnering to expand access to single-dose vials of Lilly's weight-loss drug Zepbound, which will be offered for pick-up at Walmart pharmacies nationwide by mid-November.
Read More
LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound
Published: October 29, 2025 by: PRNewsWire
Sentiment: Neutral
Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials Strategic collaboration marks the first time patients using LillyDirect, Lilly's direct-to-consumer healthcare platform, can access self-pay pricing for Zepbound vials at a retail pharmacy location LillyDirect pick-up option at Walmart offers millions of Americans living with obesity additional convenience, access and choice in how they get their medication INDIANAPOLIS , Oct. 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Walmart Inc. (NYSE: WMT) today announced a collaboration to expand access to direct-to-consumer pricing for Zepbound (tirzepatide) single-dose vials …
Read More
1 Undervalued Growth Stock Down 8% to Buy Before 2026
Published: October 28, 2025 by: The Motley Fool
Sentiment: Positive
Eli Lilly's performance over the past year hasn't been as strong as usual. The company's growth prospects justify its higher-than-average valuation.
Read More
Lilly partners with Nvidia on AI supercomputer to speed up drug development
Published: October 28, 2025 by: Reuters
Sentiment: Positive
Eli Lilly said on Tuesday it was collaborating with Nvidia to build a supercomputer to help with drug discovery and shorten development cycles, getting medicines to people faster.
Read More
Eli Lilly, Nvidia partner to build supercomputer, AI factory for drug discovery and development
Published: October 28, 2025 by: CNBC
Sentiment: Positive
Eli Lilly and Nvidia are partnering to build what the companies call the pharmaceutical industry's "most powerful" supercomputer and so-called AI factory to help accelerate drug discovery and development across the broader sector. It's the latest stride by Nvidia and the pharmaceutical industry to harness AI to try to shorten the time it takes to bring cures to patients, while reducing costs at every stage of the drug discovery and development process.
Read More
Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients
Published: October 28, 2025 by: PRNewsWire
Sentiment: Neutral
New AI capabilities will help scientists identify, optimize and validate new molecules Additional applications include manufacturing, medical imaging and enterprise AI agents INDIANAPOLIS , Oct. 28, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it is building the most powerful supercomputer owned and operated by a pharmaceutical company, in collaboration with NVIDIA. The supercomputer will power an "AI factory," a specialized computing infrastructure that manages the entire AI lifecycle from data ingestion and training to fine-tuning and high-volume inference.
Read More
Eli Lilly Partners With Nvidia to Build AI Supercomputer for Drug Discovery
Published: October 28, 2025 by: WSJ
Sentiment: Positive
The drugmaker hopes an Nvidia-chip powered supercomputer will help it find new drugs and accelerate lengthy R&D timelines.
Read More
Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings
Published: October 28, 2025 by: CNBC
Sentiment: Positive
Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.
Read More
Is It Worth Investing in Lilly (LLY) Based on Wall Street's Bullish Views?
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000